| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/30/1997 | CN1148813A Contrast medium |
| 04/30/1997 | CN1148808A Anti-acne composition |
| 04/30/1997 | CN1148806A Transdermal delivery of anti-epileptic drugs |
| 04/30/1997 | CN1148805A Method for stabilizing duocarmycin derivatives |
| 04/29/1997 | US5625075 Metal radionuclide chelating compounds for improved chelation kinetics |
| 04/29/1997 | US5624975 Plastics |
| 04/29/1997 | US5624962 For ophthalmic, dermatological and bady cavitical use |
| 04/29/1997 | US5624940 Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof |
| 04/29/1997 | US5624914 Everninomycins, cyclodextran derivative, nonionic surfactant |
| 04/29/1997 | US5624896 Clearing agents useful in pretargeting methods |
| 04/29/1997 | US5624827 DNA sequences encoding the plant toxin gelonin |
| 04/29/1997 | US5624824 Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| 04/29/1997 | US5624817 Mutations in the gene encoding the alpha chain of platelet glycoprotein Ib |
| 04/29/1997 | US5624682 Pharmaceutical formulations based on a ketoprofen solution in soft capsules, and processes for their preparation |
| 04/29/1997 | US5624680 Skin absorption of drugs with polyethersiloxane block copolymers |
| 04/29/1997 | US5624679 Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
| 04/29/1997 | US5624672 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 04/29/1997 | US5624668 Iron dextran formulations |
| 04/29/1997 | CA2003190C Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid |
| 04/24/1997 | WO1997014796A1 Monoclonal antibody br110 and uses thereof |
| 04/24/1997 | WO1997014785A2 Methods and compositions to improve germ cell and embryo survival and function |
| 04/24/1997 | WO1997014740A1 Discrete-length polyethylene glycols |
| 04/24/1997 | WO1997014442A1 Hormone immunomodulated induction of mucosal immune responses |
| 04/24/1997 | WO1997014430A1 Use of thioethers as antioxidant for peptides and proteins and compositions containing the thioethers |
| 04/24/1997 | WO1997014429A1 Stable pharmaceutical forms of administration containing parathormone |
| 04/24/1997 | WO1997014416A1 Conjugates useful in the treatment of benign prostatic hyperplasia |
| 04/24/1997 | WO1997009036A3 Improved pharmaceutical ion exchange resin composition |
| 04/24/1997 | WO1997007823A3 Compositions and their uses |
| 04/24/1997 | WO1997005267A3 Mucosal delivery of polynucleotides |
| 04/24/1997 | WO1996040055A3 Biological agent compositions |
| 04/24/1997 | WO1996034107A3 Antiviral proteins, dna coding sequences therefor, and uses thereof |
| 04/24/1997 | DE19538687A1 Stabile pharmazeutische Darreichungsformen enthaltend Parathormon The stable pharmaceutical dosage forms containing parathyroid hormone |
| 04/24/1997 | CA2234763A1 Conjugates useful in the treatment of benign prostatic hyperplasia |
| 04/24/1997 | CA2234724A1 Stable pharmaceutical forms of administration containing parathyroid hormone |
| 04/24/1997 | CA2188587A1 Support and composition containing said support and a stabilized cosmetic or dermatological ingredient |
| 04/23/1997 | EP0769294A1 Taste-masked aqueous solutions comprising methol |
| 04/23/1997 | EP0769063A1 Targeted gene delivery system |
| 04/23/1997 | EP0768897A1 Inclusion complexes of ranitidine |
| 04/23/1997 | EP0768896A2 Low-dose steroid tablets containing gallic acid esters as antioxidant agent, process for the manufacture of said tablets, and uses of said tablets |
| 04/23/1997 | EP0768882A1 Carbamazepine medicament with retarded active substance release |
| 04/23/1997 | EP0768880A1 Tacrine pharmaceutical compositions |
| 04/23/1997 | EP0768876A1 Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
| 04/23/1997 | EP0768869A1 Factor to grow tissue ex vivo |
| 04/23/1997 | EP0768826A1 Cold water-dispersible compositions of fat-soluble active substances |
| 04/23/1997 | EP0684806A4 Transmucosal delivery of macromolecular drugs. |
| 04/23/1997 | EP0600873B1 Therapeutically effective topical application of st1435 |
| 04/23/1997 | EP0596903B1 Transdermal therapeutic systems |
| 04/23/1997 | EP0593624B1 Improvements in or relating to contrast agents |
| 04/23/1997 | EP0586524B1 Improvements in or relating to contrast agents |
| 04/23/1997 | EP0583399A4 Taste-masked medicaments and their preparation |
| 04/23/1997 | EP0563249B1 Targeting of therapeutic agents using polysaccharides |
| 04/23/1997 | CN1148391A Increased bioavailability of biologically active compounds by linking to polypyrrolecarboxamido-naphthalene derivatives |
| 04/23/1997 | CN1148341A Oral liquid alendronate formulations |
| 04/23/1997 | CN1148335A Mucoadhesive emulsion contg. cyclodextrin |
| 04/23/1997 | CN1147961A Stable liquid composition containing urate oxidase and lyophilized composition for its prepn. |
| 04/22/1997 | US5623070 Modified nucleosides which form oligonucleotide mimics with improved nuclease resistance |
| 04/22/1997 | US5623064 Purity; removal of protein |
| 04/22/1997 | US5623057 Pneumococcal polysaccharide conjugate vaccine |
| 04/22/1997 | US5622978 Pharmaceutical preparations for the oral administration of dihydropyridines in beverage form |
| 04/22/1997 | US5622963 Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements |
| 04/22/1997 | US5622958 Enediyne quinone imines and methods of preparation and use thereof |
| 04/22/1997 | US5622946 Radiation sensitization using texaphyrins |
| 04/22/1997 | US5622944 Modified 17-hydroxy sterol; transdermal electrotransport enhancement |
| 04/22/1997 | US5622941 Administering the dosage form, nontoxic activated vitamin d; sustain release, side-effect reducation |
| 04/22/1997 | US5622938 Sugar base surfactant for nanocrystals |
| 04/22/1997 | US5622935 Medicine for preventing and curing bone fracture |
| 04/22/1997 | US5622933 Multiple branch peptide constructions for use against HIV |
| 04/22/1997 | US5622929 Anthracycline antibiotic; antitumor agent binds with a target cell |
| 04/22/1997 | US5622927 Mixture containing folic acid, panthenol and/or allantoin, protein hydrolysate, lactose or dextrose, lactic acid, magnesium sulfate, sodium or ammonium chloride, and a carrier; stability |
| 04/22/1997 | US5622836 Monoclonal antibodies which recognize malignant cells from bladder carcinomas |
| 04/22/1997 | US5622834 Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| 04/22/1997 | US5622722 Mixture of water soluble active drug, microcrystalline cellulose and sugar |
| 04/22/1997 | US5622721 Dosage forms of risedronate |
| 04/22/1997 | US5622718 Drug delivery; labile biodegradable spacer |
| 04/22/1997 | US5622717 Ulcer prevention method using a melt-spun hydrogel |
| 04/22/1997 | US5622712 N-[ω, (ω-1)-dialkyloxy]- and N-[ω, (ω-1)-dialkenyloxy]-alk-1-yl-N, N, N-tetrasubstituted ammonium lipids and uses therefor |
| 04/22/1997 | US5622709 Injectable |
| 04/22/1997 | US5622699 Method of identifying molecules that home to a selected organ in vivo |
| 04/22/1997 | US5622694 Water or alcohol soluble |
| 04/22/1997 | US5622690 Seed-derived proteinaceous compositions for reduction of sunburn cell formation |
| 04/22/1997 | US5622685 Tumor active or tumor diagnostic substances which exhibit preferred accumulation in tumor; reduced side effects |
| 04/22/1997 | CA2015235C Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent |
| 04/22/1997 | CA2013485C Solid consumer product compositions containing small particle cyclodextrin complexes |
| 04/17/1997 | WO1997013785A1 Transferrin receptor protein of moraxella |
| 04/17/1997 | WO1997013743A1 Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes |
| 04/17/1997 | WO1997013548A1 Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery |
| 04/17/1997 | WO1997013531A1 Solid, orally administrable viral vaccines and methods of preparation |
| 04/17/1997 | WO1997013529A1 Immunotoxin containing a disulfide-stabilized antibody fragment |
| 04/17/1997 | WO1997013528A1 A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
| 04/17/1997 | WO1997013520A1 Fast drying, film forming iodine release solution |
| 04/17/1997 | WO1997013518A1 Treatment of pruritus with vitamin d and analogs thereof |
| 04/17/1997 | WO1997013517A1 Aqueous eye drops containing apafant as principal agent |
| 04/17/1997 | WO1997013516A1 Antibacterial composition for oral administration |
| 04/17/1997 | WO1997013502A2 Prolonged release of gm-csf |
| 04/17/1997 | WO1997013499A1 Liposomal formulations of mitoxantrone |
| 04/17/1997 | WO1997013489A2 Stable extract of hypericum perforatum l., process for preparing the same and pharmaceutical compositions |
| 04/17/1997 | WO1997013482A1 Molecular transdermal transport system |
| 04/17/1997 | WO1997013410A1 Hybrid molecules containing amidated polypeptide binding ligands |
| 04/17/1997 | WO1997007788A3 Composition for sustained release of an agent |
| 04/17/1997 | WO1997003701A3 Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor |